Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 149 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06071767RecruitingPhase 1/Phase 2
Immune therapy trial for early-treated HIV
This study tests whether a combination of three immune therapies can help control HIV without daily medication. You may qualify if you started HIV treatment very early and have had a suppressed viral load for at least a year.
San Diego, CaliforniaAges 18 years+ - NCT07203365RecruitingPhase 3
RSV vaccine study for older adults in Sweden
This study tests a vaccine called Arexvy to see if it protects older adults from RSV, a virus that can cause serious lung infections. You must be born between 1965 and 1960 or before 1945, live in Sweden, and be medically stable.
SaltsjöbadenAges 60 years+ - NCT05808166RecruitingPhase 2
Hepatitis E vaccine test in healthy pregnant women
This Phase 2 study tests the safety of Hecolin® (a hepatitis E vaccine) and how well it helps the body build protection in healthy pregnant women. You might be invited if you’re pregnant during specific weeks and healthy enough for vaccination and follow-up blood tests.
Karachi, SindhAges 16–45 - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT07304284RecruitingPhase 3
Cholera vaccine study for healthy adults and people with HIV
This trial tests a new cholera vaccine (Biovac OCV-S) to see if it works as well as the current vaccine (Euvichol-Plus). It is for healthy people aged 1 to 45, and also for adults with HIV who are on treatment.
Durban, Eastern CapeAges 1–45 - NCT07207408RecruitingPhase 2
Plague vaccine study for healthy adults
This study tests an experimental vaccine to protect against plague. It's for healthy adults 18 to 55 who haven't had plague or the vaccine before. The goal is to see if the vaccine is safe and creates a strong immune response.
Miami, FloridaAges 18–55 - NCT07050732RecruitingPhase 2
Testing RSV vaccine in people with weakened immune systems
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Baltimore, MarylandAges 18 years+ - NCT07509047RecruitingPhase 2
Cholera vaccine safety study for adults and children
This trial tests a new cholera vaccine in healthy people ages 1 to 45. It aims to see if the vaccine is safe and creates a good immune response.
Nairobi, Kenyatta National Hospital ComplexAges 1–45 - NCT06997627RecruitingPhase 1/Phase 2
Safety and immune response study of GC3111B vaccine in healthy adults
This trial tests a new vaccine called GC3111B to see if it is safe and helps the body build protection against diphtheria, tetanus, and pertussis (whooping cough). It is for healthy adults who have not had a similar vaccine in the last 2 years.
SeoulAges 19–64 - NCT06694766Recruiting
Yellow Fever Vaccine Safety and Immune Response in Pregnancy
This study gathers safety and antibody information from women who received their first yellow fever vaccine either during pregnancy or outside of pregnancy. It aims to better understand how the vaccine affects pregnant women and their babies.
ParisAges 18 years+ - NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07321808Recruiting
Shingles vaccine study for frail patients
This study tests how well the shingles vaccine works in people with weakened immune systems due to conditions like rheumatoid arthritis, cancer, or multiple sclerosis. It aims to see if the vaccine is safe and effective for these patients.
Pavia, PaviaAges Any age - NCT04166656RecruitingPhase 3
Meningococcal B vaccine testing for people without a spleen
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
ParisAges 18–75 - NCT07016152RecruitingPhase 1
A study of a Klebsiella vaccine for healthy adults
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
TaipeiAges 18–50 - NCT07252804RecruitingPhase 4
Testing the MenB vaccine safety and immune response in children with rheumatic disease
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
São Paulo, São PauloAges 2–25 - NCT07242092RecruitingPhase 4
Pausing methotrexate to boost pneumonia vaccine response
This study tests whether stopping methotrexate for a short time before getting the pneumonia vaccine (PCV20) helps your body build a stronger immune response. It is for people with autoimmune rheumatic diseases like rheumatoid arthritis or lupus whose disease is under control.
São Paulo, São PauloAges 18–100 - NCT07120464Recruiting
Rabies vaccine study for people with weak immune systems or older age
This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.
Shenzhen, GuangdongAges Any age - NCT05599347RecruitingPhase 2
Azithromycin before anti-TNF treatment for Crohn’s disease
This Phase 2 trial tests whether taking azithromycin (an antibiotic) before starting infliximab or adalimumab can reduce the chance your body rejects the anti‑TNF medicine. It may help some people get better and keep responding to treatment.
Haifa, Haifa DistrictAges 18 years+ - NCT06316297RecruitingPhase 1/Phase 2
Testing a new mRNA vaccine for moderate to severe acne
This study tests an experimental mRNA vaccine designed to help the immune system fight acne-causing bacteria. It's for adults with moderate or severe facial acne who are otherwise healthy, and it may offer a new way to treat acne beyond typical creams or pills.
Scottsdale, ArizonaAges 18–45 - NCT07726147RecruitingPhase 1
Testing a new allergy shot for Japanese cedar pollen
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Tokyo, Shinjuku-kuAges 1.5 years–65 years - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75 - NCT03132311RecruitingPhase 4
Yellow fever vaccine study for certain people with HIV
This trial checks whether a yellow fever vaccine is safe and works well in adults with HIV who have relatively healthy immune function. It may help doctors understand the best way to protect people with HIV who have never had this vaccine.
Rio de JaneiroAges 18–59 - NCT03609398RecruitingPhase 2
Phase 2 study of a Rift Valley fever vaccine for safety
This study tests how safe a Rift Valley fever (RVF) vaccine is and how strongly it triggers the body’s immune response. You may be eligible if you are at risk of RVF exposure and your blood test shows you don’t already have strong protection.
Fort Deterick, MarylandAges 18–65 - NCT03878121RecruitingPhase 1
Ad4-HIV vaccine study for healthy adults and partners
This Phase 1 study tests whether an experimental HIV vaccine (made from a harmless viral vector) is safe and helps the body build immune defenses. It includes healthy volunteers and, in some groups, their close partners, with careful screening and follow-up visits.
Bethesda, MarylandAges 18–65
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 149 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.